FDA Approves Dual-Targeted Therapy for HER2-Positive Gastric Cancer First-Line Treatment

For more than a decade, patients diagnosed with advanced HER2-positive gastric cancer have relied on a single foundational therapy: trastuzumab. While effective at slowing the disease, survival rates eventually plateaued, leaving oncologists searching for a more potent way to shut down these aggressive tumors.[4]

That long-standing clinical ceiling has now been broken. The U.S. Food and Drug Administration has officially approved zanidatamab-hrii, marketed as Ziihera, as a new first-line treatment for adults with unresectable, locally advanced, or metastatic HER2-positive gastric and esophageal adenocarcinomas.[1][2]

The regulatory green light marks a fundamental shift in gastrointestinal oncology. By introducing a structurally novel drug that outperforms the old standard, the FDA has provided a highly effective new option for patients at the very start of their treatment journey, rather than waiting for older therapies to fail.[1][4]

To understand why this approval matters, it helps to look at the mechanics of the disease. HER2 is a specific protein that promotes the rapid growth of cancer cells; when tumors overexpress it, they tend to spread aggressively and require targeted intervention to halt their progression.[4]

Traditional targeted therapies like trastuzumab are monoclonal antibodies, meaning they are designed to bind to a single specific site on the HER2 protein to block its growth signals. Zanidatamab, however, belongs to a newer class of drugs known as bispecific antibodies.[1][3]

This structural difference is the key to its enhanced efficacy. Zanidatamab is engineered to bind to two distinct, non-overlapping sites on the HER2 receptor simultaneously. This dual-grip mechanism forces the receptors to cluster together, which rapidly removes them from the surface of the cancer cell and triggers a stronger immune response against the tumor.[3][4]

The clinical evidence supporting this mechanism comes from the Phase 3 HERIZON-GEA-01 trial, a massive global study that randomized 914 previously untreated patients to evaluate the new drug's real-world impact.[1][3]

The trial compared the traditional standard of care—trastuzumab combined with chemotherapy—against a new regimen featuring zanidatamab, chemotherapy, and the immunotherapy drug tislelizumab. The results were definitive and practice-changing.[2][3]

Patients receiving the zanidatamab triplet therapy achieved a median overall survival of 26.4 months. This represents a clinically meaningful improvement over the 19.2 months seen in the trastuzumab group, offering patients significantly more time.[1][3]

Furthermore, the time patients lived without their disease worsening—a metric known as progression-free survival—extended to 12.4 months with the new regimen, compared to just 8.1 months for those on the older standard.[1][3]

The FDA's authorization is notably flexible, approving two distinct regimens. Oncologists can prescribe zanidatamab alongside chemotherapy alone, or as a triplet therapy that includes tislelizumab, a PD-1 inhibitor that helps the immune system detect and destroy cancer cells.[2]

This dual-pathway approval allows physicians to tailor the intensity of the treatment to the individual patient. For those who can tolerate it, the triplet offers maximum efficacy, while the doublet provides a strong alternative for patients who might struggle with compounded side effects.[4]

To ensure the drug reaches the right patients, the FDA simultaneously approved two companion diagnostic tests. These specialized laboratory assays accurately measure HER2 expression levels in tumor tissue, confirming whether a patient meets the specific threshold required to benefit from the therapy.[2]

Despite the clear survival advantages, the transition to this new standard of care carries practical uncertainties. Combining a bispecific antibody, an immunotherapy, and traditional chemotherapy creates a complex toxicity profile that requires rigorous monitoring by care teams.[3][4]

Researchers and community oncologists will now need to determine how best to manage these side effects in real-world settings, outside the tightly controlled environment of a clinical trial, to ensure patients maintain a high quality of life during treatment.[4]

Looking ahead, the manufacturer is already investigating whether zanidatamab could be effective in earlier stages of gastric cancer. If successful, this dual-targeted approach could eventually intercept the disease before it ever has the chance to spread.[1][4]